Page results
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
T16 North is a specialist adult haematology inpatient ward dedicated to providing high-quality care for patients with a wide range of blood disorders.
-
Introduction of Bordetella pertussis PCR testing at Halo laboratory (Health Services Laboratories)
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
The psychology team at UCLH are running the next 'Navigating the exam period' group on Wednesday 19 February, from 1pm - 4pm.
-
This information is for patients who have been given a hinge knee brace.
-
A new service to provide comprehensive care and support for patients living with Sickle Cell disorder is now available in the comfort of their homes thanks to a partnership between UCLH and Whittington Health NHS Trusts.
-
Mixed sex accommodation and privacy information for patients coming into hospital for an inpatient stay
-
This information is for patients who have been given a walking boot, including air cast boots, pneumatic walking boots and vacoped boots.
File results
-
FOI/2024/0697 - Autism spectrum disorder (ASD)/ attention deficit hyperactivity disorder (ADHD) and mental health services
-
FOI/2024/0696 - Various IT systems used at Trust
-
FOI/2024/0695 - Air filtration used/ air exchange rate across Trust
-
FOI/2024/0693 - Patients overhead or ceiling track hoists portable/ mobile hoists installed
-
FOI/2024/0692 - Integrated Care Board (ICB) expenditure sign-off process 2023/24
-
FOI/2024/0691 - Information distributed to pregnant/ post-partum women for infant feeding
-
FOI/2024/0690 - Mechanical transport ventilation/ ventway sparrow transport ventilator
-
FOI/2024/0687 - Newly diagnosed patients with AML starting first line treatment - February-July 2024
-
FOI/2024/0685 - Lunch/ dinner menus for patients
-
FOI/2024/0662 - Treatment of haematology/ Myeloprolifeative diseases/ Non Hodgkin Lymphoma/ Chronic Lymphocytic Leukaemia/ Mantle Cell Lymphoma